Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tibulizumab phase 2 study in adults with hidradenitis suppurativa
2024-519736-17-00Phase 2Authorised
- Sponsor
- Zura Bio
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial in hidradenitis suppurativa (HS) comparing Tibulizumab with Placebo (2 arms). Primary endpoint: Percentage change from baseline in abscess and inflammatory nodule count at Week 16. Planned start Oct 2025; status: authorised.
02
Drugs
tibulizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2024-519736-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519736-17-00.